Carbetocin Protocols Compared for Postpartum Hemorrhage Prevention After Vaginal Delivery

Postpartum hemorrhage (PPH), defined as blood loss of 1000 ml or more, affects an estimated 14 million women annually, making it a leading cause of maternal mortality worldwide. Active management of the third stage of labor, including pharmacological agents, uterine massage, and controlled cord traction, is crucial for prevention. While oxytocin is the standard, its short half-life often necessitates continuous infusion. Carbetocin, a longer-acting oxytocin analog, offers potential advantages for PPH prevention, but optimal dosing and administration protocols remain under investigation to maximize efficacy and minimize side effects.

This completed, single-center clinical trial (NCT ID: NCT06776926) enrolled 200 women undergoing normal vaginal delivery to compare the efficacy of three distinct Carbetocin administration protocols for preventing PPH. The study aimed to determine the optimal timing for Carbetocin administration. Participants were randomized into different groups, each receiving a specific Carbetocin regimen (exact dose and timing details not specified in the abstract, but implied by "three different protocols"). The primary endpoint was the incidence of postpartum hemorrhage, defined as cumulative blood loss of 1000 ml or more.

This completed clinical trial aimed to compare the efficacy of three distinct Carbetocin protocols for preventing Postpartum Hemorrhage (PPH) after normal vaginal delivery. As of the current record, specific findings and statistical outcomes from the study are not yet publicly available. The trial concluded data collection in February 2025, and results are anticipated to be published following comprehensive analysis. Therefore, no quantitative results, p-values, or effect sizes can be reported at this time.